What Happened

Legend Biotech, Structure Therapeutics, and Revolution Medicines are identified as prime biotech M&A targets. Legend Biotech, with $1B in CAR-T revenue and J&J as a natural acquirer, is highlighted for its depressed valuation and strategic fit. Structure Therapeutics is noted for its oral GLP-1 obesity programs, while Revolution Medicines leads in oncology with its RAS(ON) inhibitor franchise.

Who Is Affected

Legend Biotech, Structure Therapeutics, and Revolution Medicines are directly affected as potential acquisition targets. Big Pharma companies, particularly those facing patent cliffs, are likely acquirers.

Market Impact

• Legend Biotech's CAR-T revenue and J&J partnership make it a strong candidate for acquisition.
• Structure Therapeutics' oral GLP-1 programs position it in a hot M&A category.
• Revolution Medicines' RAS(ON) inhibitor franchise offers significant oncology potential but comes with a high price tag.

What to Watch

Monitor Legend Biotech's valuation and J&J's potential acquisition moves. Watch Structure Therapeutics' Phase 3 registrational program and Revolution Medicines' RASolute 302 trial outcomes.